Press Release

Lupin's Goa Non Cephalosporin Oral Dosage Facility Inspected By USFDA

BSE: 500257	NSE: LUPIN	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, Jul 08, 2005: Lupin Ltd today announced that its Non Cephalosporin oral dosage facility located at Verna, Goa has sailed through US FDA inspection without any 483's. The facility, commissioned in March 2004 was set up to enable Lupin's foray in non-cephalosporin oral dosage forms for advanced markets.

Lupin Managing Director, Dr Kamal K Sharma, said, "This event re-affirms Lupin's focus in participating in the US and other advanced markets. The approval will enable Lupin to significantly enhance its product offering in US, EU and other advanced markets"

This facility at Goa would be Lupin's 11th plant to receive US FDA approval. Earlier, Lupin's non-cephalosporin API plant at Tarapur, Maharashtra also received US FDA approval without any 483's. Lupin significantly ramped up it's research spend and filed 14 ANDAs and 15 DMFs last year.

About Lupin

Headquartered in Mumbai, Lupin (http:/www.lupinworld.com) develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages. Its FY 2004-05 revenues were Rs.12 billion. 11 of Lupin's plant have been approved by the USFDA and two facilities have been approved by the UKMHRA